[Preliminary results of an open-label observational study evaluating the efficacy and safety of Prolia used in women with postmenopausal osteoporosis].

Aim: To evaluate the efficacy and safety of Denosumab (Prolia), a first-line osteoporosis (OP) medication that is a fully human monoclonal antibody to the receptor activator of nuclear factor xB ligand (RANKL), within an open-label observational study.

Subjects And Methods: Patients aged 50 years or older with postmenopausal OP, who were treated with Prolia in clinical practice, were examined. The concentrations of the bone resorption (BR) marker of C-terminal telopeptide and other laboratory indicators (total serum calcium, total alkaline phosphatase, and creatinine) were measured following 3 months.

[Clinical effects of application of taurines in patients with metabolic syndrome].

Study on the influence of taurines (Dibicor) on metabolic indicators in patients with of metabolic syndrome showed improvement in carbohydrate metabolism and lipid profile in patients with type 2 pancreatic diabetes.

[Clinical morphology of hormonally-inactive adrenal neoplasms].

94 patients with primary diagnosis "adrenal incidentaloma" were operated. Ultrasound investigation, MR-tomography, computed tomography, hormonal tests were made in examination of these patients. The results were compared with morphology and histochemistry of the removed adrenals.